ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

EDEN Eden Research Plc

3.80
-0.05 (-1.30%)
31 Oct 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.05 -1.30% 3.80 3.70 3.90 3.85 3.80 3.85 131,053 11:31:02
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 3.19M -6.49M -0.0122 -4.10 20.53M

Eden Research plc Appointment of new Head of Regulatory Affairs

15/08/2024 7:00am

RNS Non-Regulatory


RNS Number : 4804A
Eden Research plc
15 August 2024
 

15 August 2024

 

A picture containing text, clipart Description automatically generated

 

Eden Research Plc

("Eden" or "Company")

 

Appointment of new Head of Regulatory Affairs

 

Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and biocontrol technology, is pleased to announce the appointment of Ilshad Moulan as the Company's new Head of Regulatory Affairs. Ilshad will bring his experience in the agrochemical sector to lead Eden Research's regulatory strategy and execution, helping to ensure the successful global registration of its innovative crop protection solutions. 

 

Ilshad has strong expertise in regulatory affairs management having led teams and managed complex projects across the industry. With a BSc degree in Biochemistry and Cell Biology and an MSc degree in Crop Protection and Regulatory Science, his strong scientific background complements his regulatory expertise.

 

At Dr. Knoell Consult Ltd, Ilshad led a team of nine, focusing on regulatory affairs. His career began at Agrauxine, where he played a key role in developing dossiers for biopesticide active ingredients and formulated plant protection products. Additionally, his previous roles at Evergreen Garden Care and Battelle involved supporting and managing regulatory submissions for conventional active ingredients and formulated products.

 

Ilshad Moulan commented:

 

"I am thrilled to join Eden Research at such an exciting time. I look forward to using my regulatory expertise to support Eden's mission of delivering sustainable solutions to the agricultural sector and ensuring our products reach farmers worldwide as quickly and efficiently as possible."

 

Ilshad will be based at Eden Research's headquarters in Oxfordshire and will begin his new role immediately. He succeeds Dr. Mike Carroll who will retire at the end of a handover period. Mike has served as Eden's first-ever regulatory leader and played a key role in not only establishing Eden's in-house regulatory capabilities, but in successfully expanding the regulatory authorisations for Eden's existing and new products. 

 

Sean Smith, CEO of Eden Research, added:

 

"We are delighted to welcome Ilshad to our team. His extensive background in regulatory affairs, combined with his leadership skills, will be a tremendous asset as we continue to navigate the complex regulatory landscape and bring our sustainable biopesticide products to market.  At the same time, we thank Mike for all of his contributions over the past four years.  His experience and leadership have been helpful in propelling our business forward and expanding our geographical footprint, and we are grateful for all his contributions. We wish Mike all the best for a long, happy retirement."

 

 

For further information contact:

 

Eden Research plc


Sean Smith
Alex Abrey

 

www.edenresearch.com

01285 359 555



Cavendish Capital Markets Limited (Nominated advisor and broker)

 

Giles Balleny / George Lawson (corporate finance)
Charlie Combe (corporate broking)
Michael Johnson (sales)

 

020 7220 0500



Hawthorn Advisors (Financial PR)

 

Victoria Ainsworth

eden@hawthornadvisors.com

 

 

Notes to Editors:

 

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

 

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has three products currently on the market:

 

Based on plant-derived active ingredients, Mevalone® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops.  It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

 

Cedroz is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally.  Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

 

Eden's seed treatment product, Ecovelex was developed to safely tackle crop destruction caused by birds - a major cause of losses in maize and other crops. Ecovelex works by creating an unpleasant taste or odour that repels birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product is based on Eden's plant-derived chemistry, registered in the EU, U.S. and elsewhere, and formulated using Eden's Sustaine® microencapsulation system.

 

Eden's Sustaine® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.


For more information about Eden, please visit:  www.edenresearch.com.

 

 

ENDS

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAQKQBPNBKDOFD

1 Year Eden Research Chart

1 Year Eden Research Chart

1 Month Eden Research Chart

1 Month Eden Research Chart

Your Recent History

Delayed Upgrade Clock